SciClone second-quarter sales from Zadaxin up 15% at $7.9 million

By Lisa Kerner

Charlotte, N.C., Aug. 1 - SciClone Pharmaceuticals, Inc. said second-quarter 2006 revenues from the sale of its lead product, Zadaxin, increased by 15% to $7.9 million from $6.8 million for the second-quarter 2005.

Net income for the second quarter was $5.9 million, or $0.13 per share, up from the net loss of $1.5 million, or $0.03 per share, for the second-quarter 2005.

SciClone's pro forma net loss was $2 million, or $0.04 per share, for the second quarter of 2006.

For the six months ended June 30, 2006, revenues totaled $15.7 million, a 16% increase from revenues of $13.5 million for the same period of 2005.

Net income for the six-month period was $3.5 million, or $0.08 per share, up from a net loss of $2.9 million, or $0.07 per share, for same period of 2005.

Pro forma net loss was $4.5 million, or $0.10 per share, for the first half of 2006.

"Looking ahead, we expect to report Zadaxin malignant melanoma data from the large phase 2 trial ongoing in Europe in the fourth quarter and SCV-07 data from our phase 1 oral comparison trial in the third quarter of 2006," president and chief executive officer Friedhelm Blobel said in a company news release.

Cash, cash equivalents and short-term investments totaled $44.1 million at June 30, compared with cash, cash equivalents and short-term investments of $37.5 million at March 31 and $49.4 million at June 30, 2005.

SciClone is a biopharmaceutical company based in San Mateo, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.